Date: 6th November, 2026
Board Meeting Outcomes
The company has received an Observation Letter from BSE dated November 05, 2026, with 'no adverse observations' regarding the proposed Scheme of Amalgamation of Andhra Cements Limited (Transferor Company) with Sagar Cements Limited (Transferee Company). This is required under Regulation 37(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Compliance & Legal Disclosures
SEBI Comments on Draft Scheme
SEBI provided 21 specific comments/requirements in its letter dated October 30, 2026:
- Disclose all ongoing adjudication, recovery proceedings, prosecution initiated, and enforcement actions against the company, its promoters, and directors to NCLT and shareholders
- Make the scheme expressly subject to receipt of NOC from lending scheduled commercial banks/financial institutions
- Make the scheme expressly subject to receipt of report on complaints and necessary measures
- Display any additional information submitted after filing the scheme on company and stock exchange websites
- Ensure compliance with SEBI circulars issued from time to time
- Ensure all liabilities of transferor company stand transferred to transferee company
- Include information for unlisted companies in abridged prospectus format in explanatory statement
- Ensure financials in scheme including valuation report are not more than 6 months old
- Prominently disclose scheme details in notice sent to shareholders
- Include specific details in explanatory statement to shareholders:
- Need for merger, rationale, synergies, impact on shareholders, cost benefit analysis
- Details of Registered Valuer and Merchant Banker, summary of valuation methods, rationale for methods
- Basis for share swap ratio
- Pre and post scheme shareholding of both companies with rationale for changes
- Capital built-up since incorporation and last 3 years
- Revenue, PAT and EBIDTA for last 3 years
- Value of assets and liabilities being transferred and post-merger balance sheet
- Potential benefits and risks of amalgamation
- Financial implication on promoters, public shareholders, and companies with future growth prospects
- Part B of Schedule I of SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021 for NCD/NCRPS holders
- Disclose all pending actions against entities involved in the scheme, promoters, directors, KMPs
- Include additional information submitted to SEBI as part of shareholder disclosures
- Ensure equity shares issued under scheme are in demat form only
- Scheme subject to compliance with relevant clauses in scheme document
- No misstatement or false information in scheme disclosures
- No changes to draft scheme without specific written consent of SEBI
- Incorporate SEBI/stock exchange observations in NCLT petition
- Comply with all Companies Act, 2013 provisions including creditor consent
- File petitions with NCLT after SEBI/stock exchange comments processing
- Disclose No-Objection letter on website within 24 hours of receipt
BSE Conditions and Validity
- The 'no adverse observations' is limited to matters having bearing on listing/de-listing/continuous listing requirements
- The observation letter validity is six months from date of letter (November 05, 2026)
- BSE reserves right to withdraw 'no adverse observations' if information is found incomplete/incorrect/misleading/false
- The observation does not constitute SEBI approval or clearance of the scheme
- SEBI/Exchange does not take responsibility for financial soundness of the scheme or correctness of statements
Next Steps and Requirements
- The scheme is subject to statutory and regulatory approvals under applicable laws, including NCLT approval
- Company must serve notice of proposed scheme to Exchange through BSE Listing Centre online system (no physical filings accepted)
- Company must comply with Section 230(5) of Companies Act, 2013 and Rule 8 of Companies (Compromises, Arrangements and Amalgamations) Rules 2016